# InvestorDay

December 2, 2021





#### — How to ask questions to our speakers?

#### Over the phone



UK: +44 (0) 2071 928 338

France: +33 (0)1 70 70 07 81

US: +1 646 741 3167

English version only – For oral questions

Access code: 58 51 859

#### Directly from the webcast




You can submit your questions in writing directly via the platform



#### Wendel update

André François-Poncet, Group CEO David Darmon, Group Deputy CEO Jérôme Michiels, Executive Vice President and Group CFO





#### — 2021–2024 roadmap: Where do we stand?



2021 is the 1<sup>st</sup> year of our 2024 roadmap



Already some major achievements in the portfolio:

- Bureau Veritas' transformation is paying off: share price up c.+ 28.5% year -to date, Wendel stake up c.€1.2bn in value
- Sale<sup>(1)</sup> of Cromology generating c.€750m gain (7.2x multiple on our 2019 re investment)
- IHS Towers now listed on NYSE, notwithstanding current valuation materially below expectations
- Strong rebound of CPI: EBITDA now expected to significantly outperform the level achieved at acquisition



Solid financial structure allowing next moves : virtually no leverage post closing of Cromology sale and available debt capacity at several companies

#### 2021–2024 roadmapinvestmentactivity & portfolio diversification



5 firm offers to date / Tarkett acquisition closed Other bids underway before year end



Propak acquisition by Constantia Flexibles 5 bolt- on acquisitions by Bureau Veritas



#### Strengthened Investment team:

5 additional professionals recruited (+25%) over the last 12 months




#### Wendel Lab:

New hires, commitments to new funds, deployment underway

# Strong focus on capital deployment

## - Wendel's portfolio in 2024



### 9M 2021 Trading update

Jérôme Michiels, Executive Vice President & Group CFO







Portfolio companyEBITDA & leveragethroughCOVID crisis

#### Major milestones of 2024 roadmap to date

IHS Towers listed on the New York Stock Exchange on October 14, 2021

Cromology sold to Dulux Group, with net proceeds for Wendel of €907M

This valuation is €369M above the Company's valuation in Wendel's NAV
as of June 30, 2021



Wendel Lab strategy ramped up with recruitment of new talent and new capital commitments

#### Roadmapmilestones Listing of IHS Towerson the New York StockExchange

2/2: current valuation

# Analysts' coverage

- 6 analysts covering the stock, all with BUY recommendations
- Average TP of \$24.5, vs current stock price of \$14

# Valuation update

- IHS trades at c.7x 2021E EV/EBITDA vs. c.12x for Helios Towers<sup>(1)</sup>
- At current share price, Wendel's stake's worth c. €0.8bn
- Wendel analysts consensus was c. €1.4bn for Wendel stake before the IPO

### — Cromology—Wendel signed a definitive agreement for the sateromology

Wendel signed aab(e)3.3 (n955 43413.5 (904413.5 (904413.5 (904413.5 (904413.5 (904413.5 (904413.5 (904413.5 (904413.5 (90

Closing should take place during H1 2022, subject to regulatory approvals



<sup>(1)</sup> Enterprise value and EBITDA exclude the impacts of IFRS 16

<sup>(2)</sup> Net proceeds after financial debt, dilution to the benefit of the company's minority investors, transaction costs and other debt-like items

# Recent investment activity

David Darmon, Group Deputy CEO






Deployment c.€270m since the beginning of the year

€221.7m invested to acquire Tarkett's shares in partnership with the Deconinck Family as of October 26, 2021

Wendel Lab: €49m committed in 2021 to date, reaching €108m in cumulative commitments

#### Sustainediddingactivity in 2021



+ build- up opportunities solely financed by Group companies

# Quality of ESG performance acknowledge through improved ratings & distinction Extra-financial ratings







Ranked most transparent company of the SBF120 index at the 2021 Labrador Grand Prix de la Transparence (Top 3 for Chart of Ethics and ESG information)

Won the AGEFI award for Gender Diversity in Governing Bodies


#### - ESGis fully embeddeith management compensation aecentinancing

For 2021, 100 % of our controlled company CEOs have an element of variable compensation tie pe31 Tc 0.031 T5f m-en65-1.7 (1.71)]TJ ateo2.531 18.500c 0.032

94% of Wendel's employees received stock- options plan indexed on an ESG performance criteria (assessment of climate risk)

### Conclusion

André





### Concluding remarks

01



We are strongly committed to redeploying capital, targeting companies with higher growth potential

02

Most of our companies have performed well, with sales exceeding 2019 levels on an organic basis

03



Bureau Veritas has delivered outstanding operational performance and its share price rose substantially

04



We completed 3 major milestones of our 2024 roadmap: listing IHS, disposing of Cromology and ramping up Wendel Lab

<u>0</u>5

Portfolio well exposed to sustainability trends

Disclaimer

.

#### — How to ask questions to our speakers?

#### Over the phone



UK: +44 (0) 2071 928 338

France: +33 (0)1 70 70 07 81

US: +1 646 741 3167

English version only – For oral questions

Access code: 58 51 859

#### Directly from the webcast




You can submit

# **Appendix**





#### — Wendel's 2024 target portfolio & returns



(2) Ambition to reach €500m exposure in the medium term (5 to 10% of NAV)



#### Wendel'sIntegration of ESGthroughthe Investment Cycle




- 100% of all investment opportunities for which a firm offer was submitted were screened through the Investment exclusion list & an ESG Due Dilligence
- 100% of our portfolio companies have formalized an ESG roadmap (> 18 months acquisitions)



#### — Exclusionlist

In addition to refraining from investing in entities involved in the production, marketing or use of, or trade in, illegal products or activities, Wendel will also not invest in entities directly and significantly involved in the production, distribution, marketing or trading in:



- Tobacco;
- Pornography;
- Controversial weapons
- Gambling facilities or products;
- Coal mining and coal -based power generation;
- Drugs for recreational use.